Digital pathology firm PathPresenter has closed a series A funding round of $7.5 million, which the firm says it will use to accelerate the adoption of its enterprise pathology platform.
The funding was led by Avant Bio, with participation from Barco NV and Modi Ventures.
In a statement, PathPresenter noted that it would use the funds to advance the features and interoperability of its platform, reach regulatory milestones, and invest in engineering and commercial personnel.
Initially a free online platform for pathology education serving a large global digital community of pathologists, PathPresenter has built a secure and scalable enterprise platform and extended pathology use cases to include clinical care, remote consultations, and research, according to PathPresenter. The firm has collaborated with third-party vendors to create a vendor-agnostic and interoperable pathology workflow solution, it said.
The firm noted that its enterprise platform is currently used at more than 50 hospitals, labs, and pharma companies. The platform uses artificial intelligence (AI) algorithms and foundational models to "enhance patient outcomes and create new profit centers from digital pathology investments," according to PathPresenter.
